Business & Industry

Pharmaceutical and life sciences businesses face stringent requirements around batch control, traceability and compliance, which cannot be an afterthought when scaling warehouse operations and supporting pharma growth. Ryan Gibbs and Grant Smith will examine these supply chain considerations in an...

Senior officials at the US Food and Drug Administration have signaled that the agency is open to novel and innovative approaches in the clinical development of psychedelic drugs, citing the worsening mental health crisis across the United States. The...

ABEC is set to open a new manufacturing facility in Wilson, North Carolina, further strengthening its network of biopharmaceutical process equipment and consumables production. A ribbon-cutting ceremony to mark the occasion is scheduled for 24 September, with company leadership,...

The National Commission into the Regulation of AI in Healthcare has delivered its long-awaited report, setting out a framework for deploying artificial intelligence tools within the National Health Service in a manner described as "safe, fast, and trusted." Commissioned by...

Jiangsu Hengrui Pharma has secured a landmark regulatory clearance in China for its oral thrombopoietin (TPO) receptor agonist hetrombopag, making it the first oral TPO agonist anywhere in the world to receive approval for chemotherapy-induced thrombocytopenia (CIT). The approval...

Gilead Sciences has expanded its R&D infrastructure with a new 182,000-square-foot facility in Foster City dedicated to inflammation, oncology, and data science.

Novartis has signed a landmark agreement with South Korean biopharmaceutical firm Alteogen, potentially valued at up to $3.22 billion, for the development and commercialisation of subcutaneous drug formulations powered by Alteogen's proprietary ALT-B4 technology. A Multi-Option Agreement Targeting Subcutaneous Formulation The...